Management of needlestick injuries: A house officer who has a needlestick

JAMA

Volumn 307, Issue 1, 2012, Pages 75-84

  Henderson, David K ^a  

^a Natl Inst of Hlth Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

APPETITE DISORDER; CONFERENCE PAPER; DIARRHEA; DIZZINESS; DYSGEUSIA; FATIGUE; HEADACHE; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MALAISE; NAUSEA; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PATIENT COUNSELING; PRIORITY JOURNAL; RISK REDUCTION; SEROCONVERSION; SEROLOGY; STOMACH PAIN; VOMITING; WEAKNESS; WORKPLACE;

EID: 84855414463     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1828     Document Type: Conference Paper

References (99)

1. Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. (Pubitemid 351632017)
2. Schmid K, Schwager C, Drexler H. Needlestick injuries and other occupational exposures to body fluids amongst employees and medical students of a German university: incidence and follow-up. J Hosp Infect. 2007;65(2):124-130. (Pubitemid 46505913)
3. Tadesse M, Tadesse T. Epidemiology of needlestick injuries among health-care workers in Awassa City, southern Ethiopia. Trop Doct. 2010;40(2):111-113.
4. Venier AG, Vincent A, L'heriteau F, et al. Surveillance of occupational blood and body fluid exposures among French healthcare workers in 2004. Infect Control Hosp Epidemiol. 2007;28(10):1196-1201. (Pubitemid 47580465)
5. Porta C, Handelman E, McGovern P. Needlestick injuries among health care workers: a literature review. AAOHN J. 1999;47(6):237-244. (Pubitemid 29279310)
6. Panlilio AL, Orelien JG, Srivastava PU, Jagger J, Cohn RD, Cardo DM; NaSH Surveillance Group; EPINet Data Sharing Network. Estimate of the annual number of percutaneous injuries among hospital-based healthcare workers in the United States, 1997-1998. Infect Control Hosp Epidemiol. 2004;25(7):556-562. (Pubitemid 38954485)
7. Beltrami EM, McArthur MA, McGeer A, et al. The nature and frequency of blood contacts among home healthcare workers. Infect Control Hosp Epidemiol. 2000;21(12):765-770. (Pubitemid 32010219)
8. Burke S, Madan I. Contamination incidents among doctors and midwives: reasons for non-reporting and knowledge of risks. Occup Med (Lond). 1997;47(6):357-360. (Pubitemid 27416863)
9. Hamory BH. Underreporting of needlestick injuries in a university hospital. Am J Infect Control. 1983;11(5):174-177. (Pubitemid 14242078)
10. Mangione CM, Gerberding JL, Cummings SR. Occupational exposure to HIV: frequency and rates of underreporting of percutaneous and mucocutaneous exposures by medical housestaff. Am J Med. 1991;90(1):85-90.
11. Radecki S, Abbott A, Eloi L. Occupational human immunodeficiency virus exposure among residents and medical students: an analysis of 5-year follow-up data. Arch Intern Med. 2000;160(20):3107-3111.
12. Henderson DK. HIV in the healthcare setting. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. New York, NY: Elsevier Churchill Livingstone; 2009:3753-3770.
13. Ippolito G, Puro V, Heptonstall J, Jagger J, De Carli G, Petrosillo N. Occupational human immunodeficiency virus infection in health care workers: worldwide cases through September 1997. Clin Infect Dis. 1999;28(2):365-383. (Pubitemid 29241227)
14. Fahey BJ, Koziol DE, Halker E, Henderson DK. Cutaneous exposures to blood and other body fluids among healthcare workers in the OSHA bloodborne pathogens standard era. Paper presented at: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 1995; San Francisco, CA.
15. Seeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of the Veterans Administration Cooperative Study. Ann Intern Med. 1978;88(3):285-293. (Pubitemid 8287458)
16. Werner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med. 1982;97(3):367-369. (Pubitemid 12061585)
17. Henderson DK. Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev. 2003;16(3):546-568. (Pubitemid 36871321)
18. Bennett NT, Howard RJ. Quantity of blood inoculated in a needlestick injury from suture needles. J Am Coll Surg. 1994;178(2):107-110. (Pubitemid 24073485)
19. Mast ST, Woolwine JD, Gerberding JL. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. J Infect Dis. 1993;168(6):1589-1592. (Pubitemid 23344932)
20. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997;3(5):549-552. (Pubitemid 27198654)
21. + lymphocyte levels. J Infect Dis. 1991;164(1):72-80.
22. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1996;335(22):1621-1629. (Pubitemid 26392726)
23. Cardo DM, Culver DH, Ciesielski CA, et al Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337(21):1485-1490. (Pubitemid 27495773)
24. Rowland-Jones S, Dong T, Krausa P, et al. The role of cytotoxic T-cells in HIV infection. Dev Biol Stand. 1998;92:209-214.
25. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995;1(1):59-64.
26. Clerici M, Giorgi JV, Chou CC, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis. 1992;165(6):1012-1019.
27. Kelker HC, Seidlin M, Vogler M, Valentine FT. Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens. AIDS Res Hum Retroviruses. 1992;8(8):1355-1359.
28. Mazzoli S, Trabattoni D, Lo Caputo S, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med. 1997;3(11):1250-1257. (Pubitemid 27508826)
29. Cheynier R, Langlade-Demoyen P, Marescot MR, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol. 1992;22(9):2211-2217.
30. Missale G, Papagno L, Penna A, et al. Parenteral exposure to high HIV viremia leads to virus-specific T cell priming without evidence of infection. Eur J Immunol. 2004;34(11):3208-3215. (Pubitemid 39549399)
31. Clerici M, Levin JM, Kessler HA, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA. 1994;271(1):42-46. (Pubitemid 24020578)
32. Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997;102(5B):21-24. (Pubitemid 27334741)
33. Pinto LA, Sullivan J, Berzofsky JA, et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest. 1995;96(2):867-876.
34. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36(4 pt 1):993-1000.
35. Centers for Disease Control. Recommendations for prevention of HIV transmission in health-care settings. MMWR Morb Mortal Wkly Rep. 1987;36(suppl 2):1S-18S.
36. Garner JS; Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17(1):53-80.
37. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep. 1988;37(24):377-382, 387-388.
38. Beekmann SE, Vlahov D, Koziol DE, McShalley ED, Schmitt JM, Henderson DK. Temporal association between implementation of universal precautions and a sustained, progressive decrease in percutaneous exposures to blood. Clin Infect Dis. 1994;18(4):562-569. (Pubitemid 24106908)
39. Haiduven DJ, DeMaio TM, Stevens DA. A five-year study of needlestick injuries: significant reduction associated with communication, education, and convenient placement of sharps containers. Infect Control Hosp Epidemiol. 1992;13(5):265-271.
40. Kristensen MS, Wernberg NM, Anker-Møller E. Healthcare workers' risk of contact with body fluids in a hospital: the effect of complying with the universal precautions policy. Infect Control Hosp Epidemiol. 1992;13(12):719-724.
41. Alvarado-Ramy F, Beltrami EM, Short LJ, et al. A comprehensive approach to percutaneous injury prevention during phlebotomy: results of a multicenter study, 1993-1995. Infect Control Hosp Epidemiol. 2003;24(2):97-104. (Pubitemid 36206077)
42. Centers for Disease Control and Prevention. Evaluation of safety devices for preventing percutaneous injuries among health-care workers during phlebotomy procedures: Minneapolis-St Paul, New York City, and San Francisco, 1993-1995. MMWR Morb Mortal Wkly Rep. 1997;46(2):21-25.
43. Haiduven DJ, Phillips ES, Clemons KV, Stevens DA. Percutaneous injury analysis: consistent categorization, effective reduction methods, and future strategies. Infect Control Hosp Epidemiol. 1995;16(10):582-589.
44. Mendelson MH, Lin-Chen BY, Solomon R, Bailey E, Kogan G, Goldbold J. Evaluation of a safety resheathable winged steel needle for prevention of percutaneous injuries associated with intravascular-access procedures among healthcare workers. Infect Control Hosp Epidemiol. 2003;24(2):105-112. (Pubitemid 36206078)
45. Akduman D, Kim LE, Parks RL, et al. Use of personal protective equipment and operating room behaviors in four surgical subspecialties: personal protective equipment and behaviors in surgery. Infect Control Hosp Epidemiol. 1999;20(2):110-114.
46. Davis JM, Demling RH, Lewis FR, Hoover E, Waymack JP; Ad Hoc Committee on Acquired Immunodeficiency Syndrome and Hepatitis. The Surgical Infection Society's policy on human immunodeficiency virus and hepatitis B and C infection. Arch Surg. 1992;127(2):218-221.
47. Loudon MA, Stonebridge PA. Minimizing the risk of penetrating injury to surgical staff in the operating theatre: towards sharp-free surgery. J R Coll Surg Edinb. 1998;43(1):6-8. (Pubitemid 28143515)
48. Aarnio P, Laine T. Glove perforation rate in vascular surgery - a comparison between single and double gloving. Vasa. 2001;30(2):122-124. (Pubitemid 32531269)
49. Avery CM, Taylor J, Johnson PA. Double gloving and a system for identifying glove perforations in maxillofacial trauma surgery. Br J Oral Maxillofac Surg. 1999;37(4):316-319. (Pubitemid 29386826)
50. Chapman S, Duff P. Frequency of glove perforations and subsequent blood contact in association with selected obstetric surgical procedures. Am J Obstet Gynecol. 1993;168(5):1354-1357. (Pubitemid 23153271)
51. Gerberding JL, Littell C, Tarkington A, Brown A, Schecter WP. Risk of exposure of surgical personnel to patients' blood during surgery at San Francisco General Hospital. N Engl J Med. 1990;322(25):1788-1793. (Pubitemid 20194658)
52. Kovavisarach E, Seedadee C. Randomised controlled trial of glove perforation in single and double-gloving methods in gynaecologic surgery. Aust N Z J Obstet Gynaecol. 2002;42(5):519-521. (Pubitemid 35385692)
53. Laine T, Aarnio P. How often does glove perforation occur in surgery? comparison between single gloves and a double-gloving system. Am J Surg. 2001;181(6):564-566. (Pubitemid 32769986)
54. Naver LP, Gottrup F. Incidence of glove perforations in gastrointestinal surgery and the protective effect of double gloves: a prospective, randomised controlled study. Eur J Surg. 2000;166(4):293-295. (Pubitemid 30235779)
55. Gerberding JL, Quebbeman EJ, Rhodes RS. Hand protection. Surg Clin North Am. 1995;75(6):1133-1139.
56. Leslie LF, Woods JA, Thacker JG, Morgan RF, McGregor W, Edlich RF. Needle puncture resistance of surgical gloves, finger guards, and glove liners. J Biomed Mater Res. 1996;33(1):41-46. (Pubitemid 26094606)
57. Woods JA, Leslie LF, Drake DB, Edlich RF. Effect of puncture resistant surgical gloves, finger guards, and glove liners on cutaneous sensibility and surgical psychomotor skills. J Biomed Mater Res. 1996;33(1):47-51. (Pubitemid 26096415)
58. US Public Health Service. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR-11):1-52.
59. Gerberding JL, Henderson DK. Design of rational infection control policies for human immunodeficiency virus infection. J Infect Dis. 1987;156(6):861-864. (Pubitemid 18017059)
60. Incident Investigation Teams. Transmission of hepatitis B to patients from 4 infected surgeons without hepatitis B e antigen. N Engl J Med. 1997;336(3):178-184.
61. Gerberding JL. Postexposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Am J Med. 1997;102(5B):85-89. (Pubitemid 27334755)
62. Henderson DK. HIV postexposure prophylaxis in the 21st century. Emerg Infect Dis. 2001;7(2):254-258. (Pubitemid 32374339)
63. Beekmann SE, Henderson DK. Health care workers and hepatitis: risk for infection and management of exposures. Infect Dis Clin Pract. 1992;1(6):424-428.
64. Jaeckel E, Cornberg M, Wedemeyer H, et al; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452-1457.
65. Blauvelt A, Glushakova S, Margolis LB. HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. AIDS. 2000;14(6):647-651. (Pubitemid 30229343)
66. + T cells. J Exp Med. 1995;182(6):2045-2056.
67. Granelli-Piperno A, Finkel V, Delgado E, Steinman RM. Virus replication begins in dendritic cells during the transmission of HIV-1 from mature dendritic cells to T cells. Curr Biol. 1999;9(1):21-29. (Pubitemid 29045791)
68. Böttiger D, Johansson NG, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS. 1997;11(2):157-162. (Pubitemid 27055400)
69. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72(5):4265-4273. (Pubitemid 28188732)
70. Tsai CC, Emau P, Sun JC, et al. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J Med Primatol. 2000;29(3-4):248-258.
71. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270(5239):1197-1199.
72. van Rompay KK, Dailey PJ, Tarara RP, et al. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. J Virol. 1999;73(4):2947-2955. (Pubitemid 29135683)
73. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-1180. (Pubitemid 24331334)
74. Bulterys M, Orloff S, Abrams E, et al. mpact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: a prospective cohort study in 4 US cities (abstract 15). I Paper presented at: Global Strategies for the Prevention of HIV Transmission From Mothers to Infants; September 1-6, 1999; Toronto, ON, Canada.
75. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339(20):1409-1414. (Pubitemid 28516063)
76. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995;44(50):929-933.
77. Henderson DK, Gerberding JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis. 1989;160(2):321-327. (Pubitemid 19189026)
78. Do AN, Ciesielski CA, Metler RP, Hammett TA, Li J, Fleming PL. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol. 2003;24(2):86-96. (Pubitemid 36206076)
79. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect. 2003;9(3):186-193. (Pubitemid 36511677)
80. Lalezari JP, Henry K, O'Hearn M, et al; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175-2185. (Pubitemid 36618128)
81. Méchai F, Quertainmont Y, Sahali S, Delfraissy JF, Ghosn J. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J Med Virol. 2008;80(1):9-10. (Pubitemid 350220083)
82. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; US Public Health Service. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005;54(RR-9):1-17.
83. Gallant JE, DeJesus E, Arribas JR, et al Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260. (Pubitemid 43113030)
84. Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010;24(15):2375-2380.
85. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47(4):494-499. (Pubitemid 351366963)
86. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004;39(3):395-401. (Pubitemid 39050489)
87. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001;49(51-52):1153-1156.
88. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med. 2002;137(2):146-147. (Pubitemid 34784613)
89. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284(21):2723.
90. Luque A, Hulse S, Wang D, et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701. (Pubitemid 46954756)
91. Wang SA, Panlilio AL, Doi PA, White AD, Stek M Jr, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol. 2000;21(12):780-785. (Pubitemid 32010222)
92. Armstrong K, Gorden R, Santorella G. Occupational exposure of health care workers (HCWs) to human immunodeficiency virus (HIV): stress reactions and counseling interventions. Soc Work Health Care. 1995;21(3):61-80.
93. Dilley JW. Counseling health care workers after accidental exposures. Focus. 1990;5:3-4.
94. Henderson DK. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA. 1999;281(10):931-936. (Pubitemid 29124638)
95. Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford G. Antiretroviral postexposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007;(1):CD002835.
96. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis. 2001;183(5):707-714. (Pubitemid 32171744)
97. Roland ME, Martin JN, Grant RM, et al. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis. 2001;184(12):1608-1612. (Pubitemid 33139749)
98. Doebbeling BN, Vaughn TE, McCoy KD, et al. Percutaneous injury, blood exposure, and adherence to standard precautions: are hospital-based health care providers still at risk? Clin Infect Dis. 2003;37(8):1006-1013. (Pubitemid 37323653)
99. Quinn MM, Markkanen PK, Galligan CJ, et al. Sharps injuries and other blood and body fluid exposures among home health care nurses and aides. Am J Public Health. 2009;99(suppl 3):S710-S717.